Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism
暂无分享,去创建一个
G. Battaglia | V. Bruno | R. Gradini | G. Molinaro | M. Motolese | M. Cannella | D. Bucci | F. Nicoletti | Marta Motolese
[1] Kari A. Johnson,et al. Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS , 2014, The Journal of Neuroscience.
[2] R. Hodgson,et al. A2A receptor antagonists do not induce dyskinesias in drug-naive or l-dopa sensitized rats , 2013, Brain Research Bulletin.
[3] F. Nicoletti,et al. Early Life Stress Causes Refractoriness to Haloperidol-Induced Catalepsy , 2013, Molecular Pharmacology.
[4] F. Gasparini,et al. Metabotropic Glutamate Receptors for Parkinson's Disease Therapy , 2013, Parkinson's disease.
[5] C. Bass,et al. Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and delta opioid systems , 2013, Journal of neurochemistry.
[6] G. Fisone,et al. Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease , 2013, Neuropharmacology.
[7] KouichiC . Nakamura,et al. Dichotomous Organization of the External Globus Pallidus , 2012, Neuron.
[8] Kuei Yuan Tseng,et al. CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation , 2012, Front. Pharmacol..
[9] F. Nicoletti,et al. Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.
[10] S. Bicciato,et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation , 2010, Nature Medicine.
[11] L. Grégoire,et al. Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys , 2010, Journal of neurochemistry.
[12] P Jeffrey Conn,et al. Glutamate receptors as therapeutic targets for Parkinson's disease. , 2009, CNS & neurological disorders drug targets.
[13] A. Bittner,et al. Dopamine Depletion Induces Distinct Compensatory Gene Expression Changes in DARPP-32 Signal Transduction Cascades of Striatonigral and Striatopallidal Neurons , 2009, The Journal of Neuroscience.
[14] J. Brotchie,et al. Mechanisms compensating for dopamine loss in early Parkinson disease , 2009, Neurology.
[15] R. Moratalla,et al. Expression and Function of CB1 Receptor in the Rat Striatum: Localization and Effects on D1 and D2 Dopamine Receptor-Mediated Motor Behaviors , 2008, Neuropsychopharmacology.
[16] R. Sanchez-Pernaute,et al. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates , 2008, NeuroImage.
[17] F. Fonseca,et al. Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1 , 2008, Neuropharmacology.
[18] Vesna Sossi,et al. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study , 2007, Annals of neurology.
[19] M. Amalric,et al. Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease , 2007, The Journal of Neuroscience.
[20] Robert C. Malenka,et al. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.
[21] Mauro Piacentini,et al. Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders , 2007, Journal of neurochemistry.
[22] T. Freund,et al. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia , 2006, Neuroscience.
[23] G. Bernardi,et al. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia , 2006, Neurobiology of Disease.
[24] A. Verkhratsky,et al. Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats. , 2006, European journal of pharmacology.
[25] F. Nicoletti,et al. Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine , 2006, The Journal of Neuroscience.
[26] P. Jeffrey Conn,et al. Metabotropic glutamate receptors in the basal ganglia motor circuit , 2005, Nature Reviews Neuroscience.
[27] E. Bézard,et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease , 2005, Neuropharmacology.
[28] J. Marshall,et al. Glutamic Acid Decarboxylase 67 mRNA Regulation in Two Globus Pallidus Neuron Populations by Dopamine and the Subthalamic Nucleus , 2004, The Journal of Neuroscience.
[29] Giuseppe Battaglia,et al. Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.
[30] L F Agnati,et al. Receptor heteromerization in adenosine A2A receptor signaling , 2003, Neurology.
[31] O. Valenti,et al. Modulation of Inhibitory Transmission in the Rat Globus Pallidus by Activation of mGluR4 , 2003, Annals of the New York Academy of Sciences.
[32] P Jeffrey Conn,et al. Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.
[33] Erwan Bezard,et al. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated , 2003, Trends in Neurosciences.
[34] Michael A King,et al. Particle detection, number estimation, and feature measurement in gene transfer studies: optical fractionator stereology integrated with digital image processing and analysis. , 2002, Methods.
[35] S. Duty,et al. Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract , 2002, Neuropharmacology.
[36] P. Somogyi,et al. Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS , 2002, Neuroscience.
[37] G. Marsicano,et al. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain , 2002, Neuroscience.
[38] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[39] T. Hökfelt,et al. Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats , 1999, Neuroscience.
[40] K. Kovács,et al. Invited review c-Fos as a transcription factor: a stressful (re)view from a functional map , 1998, Neurochemistry International.
[41] K. Starke,et al. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum , 1998, Neuroscience.
[42] P. Calabresi,et al. Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors , 1997, The Journal of Neuroscience.
[43] J. Surmeier,et al. D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. , 1997, Journal of neurophysiology.
[44] E. Abercrombie,et al. Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors. , 1996, European journal of pharmacology.
[45] J. Roder,et al. Impaired Cerebellar Synaptic Plasticity and Motor Performance in Mice Lacking the mGluR4 Subtype of Metabotropic Glutamate Receptor , 1996, The Journal of Neuroscience.
[46] E. Hirsch,et al. Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum , 1995, Neuroscience.
[47] C. Marsden,et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease , 1995, Neuroscience.
[48] A. Parent,et al. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys , 1994, Neuroreport.
[49] D. Mash,et al. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.
[50] B. Lipska,et al. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. , 1993, Brain research. Developmental brain research.
[51] J. Vanderhaeghen,et al. Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum , 1992, Neuroscience Letters.
[52] P. M. Groves,et al. A GABA immunocytochemical study of rat motor thalamus: Light and electron microscopic observations , 1991, Neuroscience.
[53] A. Duchemin,et al. Preproenkephalin mRNA and Methionine‐Enkephalin Increase in Mouse Striatum After 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Treatment , 1991, Journal of neurochemistry.
[54] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[55] R. Faull,et al. The use of c-fos as a metabolic marker in neuronal pathway tracing , 1989, Journal of Neuroscience Methods.
[56] G Maura,et al. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. , 1988, The Journal of pharmacology and experimental therapeutics.
[57] M. Zigmond,et al. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. , 1984, Archives of neurology.
[58] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[59] P. Jeffrey Conn,et al. Development of allosteric modulators of GPCRs for treatment of CNS disorders , 2014, Neurobiology of Disease.
[60] G. Zetler,et al. Pharmacokinetics and effects of haloperidol in the isolated mouse. , 1985, Pharmacology.